Multicenter, open-label, single-group study evaluating the long-term safety and tolerability of fingolimod 0.5 mg (FTY720) administered orally once a day in patients with multiple sclerosis redicivant forms
Novartis Farmaceutica, S.A.
Pathology and candidate patients
Dr. Luís Martí Bonmatí
Hospital Quirónsalud Valencia.
Fingolimod 0,5 mg (FTY720)
December 1, 2011
Hospital Universitario La Fe
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the image diagnosis team by sending an email to the address: email@example.com